Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Name: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Published: 2023
License: Public Domain

Aadi Bioscience, Inc. · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

net

neuroendocrine tumors, net, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumor, pulmonary neuroendocrine tumor, fyarro, nab-sirolimus, abi-009, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Related documents